Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA363352
Max Phase: Preclinical
Molecular Formula: C17H17ClN2O3S
Molecular Weight: 364.85
Molecule Type: Small molecule
Associated Items:
ID: ALA363352
Max Phase: Preclinical
Molecular Formula: C17H17ClN2O3S
Molecular Weight: 364.85
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC/C=C\COC1(c2ccc(Cl)cc2)SC=C(C)n2c1noc2=O
Standard InChI: InChI=1S/C17H17ClN2O3S/c1-3-4-5-10-22-17(13-6-8-14(18)9-7-13)15-19-23-16(21)20(15)12(2)11-24-17/h4-9,11H,3,10H2,1-2H3/b5-4-
Standard InChI Key: FHQCBTSYENFAFR-PLNGDYQASA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 364.85 | Molecular Weight (Monoisotopic): 364.0648 | AlogP: 4.24 | #Rotatable Bonds: 5 |
Polar Surface Area: 57.26 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 0 |
#RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: | CX LogP: 4.94 | CX LogD: 4.94 |
Aromatic Rings: 2 | Heavy Atoms: 24 | QED Weighted: 0.74 | Np Likeness Score: -0.40 |
1. Budriesi R, Carosati E, Chiarini A, Cosimelli B, Cruciani G, Ioan P, Spinelli D, Spisani R.. (2005) A new class of selective myocardial calcium channel modulators. 2. Role of the acetal chain in oxadiazol-3-one derivatives., 48 (7): [PMID:15801835] [10.1021/jm0493414] |
2. Viale M, Cordazzo C, Cosimelli B, de Totero D, Castagnola P, Aiello C, Severi E, Petrillo G, Cianfriglia M, Spinelli D.. (2009) Inhibition of MDR1 activity in vitro by a novel class of diltiazem analogues: toward new candidates., 52 (2): [PMID:19093883] [10.1021/jm801195k] |
3. Rosano C, Viale M, Cosimelli B, Severi E, Gangemi R, Ciogli A, De Totero D, Spinelli D.. (2013) ABCB1 Structural Models, Molecular Docking, and Synthesis of New Oxadiazolothiazin-3-one Inhibitors., 4 (8): [PMID:24900735] [10.1021/ml300436x] |
4. Cuviello F, Bisaccia F, Spinelli D, Armentano MF, Bufo SA, Cosimelli B, Ostuni A.. (2019) The P-glycoprotein inhibitor diltiazem-like 8-(4-chlorophenyl)-5-methyl-8-[(2Z)-pent-2-en-1-yloxy]-8H-[1,2,4]oxadiazolo[3,4-c][1,4]thiazin-3-one inhibits esterase activity and H3 histone acetylation., 164 [PMID:30583246] [10.1016/j.ejmech.2018.12.037] |
Source(1):